Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Atara Biotherapeutics, Inc. (NASDAQ: ATRA).

Full DD Report for ATRA

You must become a subscriber to view this report.


Recent News from (NASDAQ: ATRA)

Atara Biotherapeutics (ATRA) Presents At 4th Annual CAR-TCR Summit 2018 - Slideshow
The following slide deck was published by Atara Biotherapeutics in conjunction with this Read more ...
Source: SeekingAlpha
Date: September, 06 2018 14:53
Atara Biotherapeutics and Moffitt Cancer Center collaborates to develop next-generation CAR T immunotherapies
Atara Biotherapeutics (NASDAQ: ATRA ) has entered into a strategic collaboration with Moffitt Cancer Center to develop multi-targeted chimeric antigen receptor T-cell ((CAR T)) immunotherapies for patients with AML and B-cell malignancies. More news on: Atara Biotherapeutics, Healthcare ...
Source: SeekingAlpha
Date: September, 06 2018 09:15
Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies
Focus on multi-targeted CAR T immunotherapies for patients with acute myelogenous leukemia (AML) and B-cell malignancies Collaboration includes novel CAR T targeting and signaling domains designed to optimize T cell proliferation and enhance persistence SOUTH SAN FRANCISCO, Ca...
Source: GlobeNewswire
Date: September, 06 2018 07:30
Atara Biotherapeutics to Participate at Two Upcoming Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that members of the...
Source: GlobeNewswire
Date: August, 31 2018 08:00
Pfizer mid-stage flop with domagrozumab in DMD another setback for myostatin inhibitors - Endpoints News
Endpoints News' John Carroll reports that Pfizer's failure with domagrozumab in Duchenne muscular dystrophy (DMD) is another black eye for myostatin inhibitors for muscle wasting disorders. More news on: Novartis AG, Amgen Inc., Atara Biotherapeutics, Healthcare stocks news, Read mor...
Source: SeekingAlpha
Date: August, 30 2018 12:36
Bulletproof Investing Performance Update: Week 38
Safety first: Sprint car driver McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 38 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This...
Source: SeekingAlpha
Date: August, 16 2018 16:05
Analysis: Positioning to Benefit within Quanex Building Products, Molecular Templates, Atara Biotherapeutics, Forward Industries, Apollo Endosurgery, and Myomo - Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK,, Aug. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Quanex Building Products Corporation (NYSE:NX), Molecular Templates Inc....
Source: GlobeNewswire
Date: August, 16 2018 07:40
Tracking Seth Klarman's Baupost Group Holdings - Q2 2018 Update
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman’s regulatory 13F Form filed on 08/13/2018. Please visit our Tracking Seth Klarman’s Baupost Group Holdings ...
Source: SeekingAlpha
Date: August, 14 2018 05:08
Atara Biotherapeutics Announces Second Quarter 2018 Financial Results and Recent Operational Progress
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results fo...
Source: GlobeNewswire
Date: August, 01 2018 08:00
Atara Biotherapeutics to Participate in the Canaccord Genuity 38th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Christopher Ha...
Source: GlobeNewswire
Date: July, 31 2018 16:45

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0838.3539.7540.6538.00929,610
2018-05-1747.1047.9048.0546.35565,043
2017-06-2013.4513.5013.8513.30242,367
2017-06-1912.8013.4513.9512.75308,051
2017-06-1612.2012.7513.4012.15863,129

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1150,22573,11568.6932Short
2018-12-1061,86997,07063.7365Short
2018-12-0754,53477,71970.1682Short
2018-12-0633,06257,80957.1918Short
2018-12-0448,210125,40438.4437Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ATRA.


About Atara Biotherapeutics, Inc. (NASDAQ: ATRA)

Logo for Atara Biotherapeutics, Inc. (NASDAQ: ATRA)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ATRA)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 26 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 26 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: April, 10 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: April, 09 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: April, 03 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 02 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: March, 01 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: March, 01 2018

       

       


      Daily Technical Chart for (NASDAQ: ATRA)

      Daily Technical Chart for (NASDAQ: ATRA)


      Stay tuned for daily updates and more on (NASDAQ: ATRA)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ATRA)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ATRA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ATRA and does not buy, sell, or trade any shares of ATRA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/